Publicacions en què col·labora amb Rosario Palacios Muñoz (6)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5